Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy

Rhea-AI Filing Summary

Anika Therapeutics, Inc. director John B. Henneman III reported an open-market purchase of 5,000 shares of common stock at a weighted average price of $14.6639 per share. Following this transaction, he directly holds 54,871 shares. The shares were bought in multiple trades between $14.595 and $14.75.

Insider Trade Summary

Net Buyer: 5,000 shares ($73,320)

Net Buy 1 txn

Insider HENNEMAN JOHN B III

Role null

Bought 5,000 shs ($73K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$14.6639	$73K

Holdings After Transaction: Common Stock — 54,871 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 5,000 shares Weighted average price: $14.6639 per share Post-transaction holdings: 54,871 shares +1 more

4 metrics

Shares purchased 5,000 shares Open-market purchase of common stock

Weighted average price $14.6639 per share Price for the 5,000-share purchase

Post-transaction holdings 54,871 shares Shares directly owned after the trade

Price range of trades $14.595–$14.75 per share Range of individual trade prices on transaction date

Key Terms

open-market purchase, weighted average price, transaction code "P"

3 terms

open-market purchase financial

"reported an open-market purchase of 5,000 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

transaction code "P" regulatory

"transaction code "P" indicating a purchase in open market"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENNEMAN JOHN B III

(Last) (First) (Middle)

C/O ANIKA THERAPEUTICS, INC.

32 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		P		5,000	A	$14.6639(1)	54,871	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.595 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ John B. Henneman, III	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Anika Therapeutics (ANIK) report?

Anika Therapeutics reported that director John B. Henneman III made an open-market purchase of 5,000 shares of common stock. The transaction was reported on a Form 4 insider trading filing with the SEC, detailing price and post-transaction ownership.

At what price did the ANIK director buy the 5,000 shares?

The director bought 5,000 ANIK shares at a weighted average price of $14.6639 per share. According to the filing footnote, individual trades occurred in a price range between $14.595 and $14.75, all on the same transaction date.

How many Anika Therapeutics shares does the insider own after this trade?

After the reported purchase, the director directly owns 54,871 shares of Anika Therapeutics common stock. This total reflects his holdings immediately following the 5,000-share open-market buy disclosed in the Form 4 insider filing.

Was the ANIK insider transaction a purchase or a sale?

The ANIK insider transaction was a purchase. The Form 4 filing classifies it as an open-market purchase of 5,000 shares under transaction code "P," indicating a buy rather than a sale or other type of disposition.

How was the purchase price for the ANIK insider transaction determined?

The filing reports a weighted average purchase price of $14.6639 per share. A footnote explains the shares were bought in multiple trades, with individual prices ranging from $14.595 to $14.75, and full trade details are available upon request.